Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Coleman, RE, Collinson, M orcid.org/0000-0003-3568-6455, Gregory, W orcid.org/0000-0003-2641-8416 et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13. pp. 123-135. ISSN 2212-1374

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Dates:
  • Published: November 2018
  • Accepted: 16 September 2018
  • Published (online): 27 September 2018
Institution: The University of Leeds
Academic Units: ?? Leeds.SU-LI67 ??
?? Leeds.SU-LI44 ??
Depositing User: Symplectic Publications
Date Deposited: 23 Jan 2019 11:07
Last Modified: 23 Jan 2019 11:07
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.jbo.2018.09.008

Share / Export

Statistics